NCT05305924View on ClinicalTrials.gov

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
ER-Positive Breast CancerHER2-negative Breast Cancer
Interventions
DRUG

Fulvestrant Run-In

The study is evaluating if a drug holiday (post CDK inhibitors progression) will reset the cell cycle machinery to be responsive to Abemaciclib and Fulvestrant.

Trial Locations (1)

77030

RECRUITING

Houston Methodist Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

The Methodist Hospital Research Institute

OTHER